• Hub Login
  • Contact
  • Investors
  • Viveve Solutions
    • Viveve System
    • InControl by Viveve
  • Clinical Studies
  • About
    • Mission
    • Leadership
    • Careers
  • News
    • Blog
    • Media & Press
    • Investor News
    • Events
  • Testimonials
Select Page
Dev Site

A Global Women’s Intimate Health Company

Historical Data

Investors
  • Overview
  • News / Events
    • Overview
    • Press Releases
    • Publications
    • IR Calendar
    • Analyst Coverage
    • Email Alerts
  • Company Info
    • Overview
    • Management Team
    • Advisory Board
    • Presentations
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Balance Sheet
    • Income Statement
    • Cash Flow
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Annual Reports
    • Quarterly Reports
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Board Committees
    • Governance Documents
  • Investor Tools
    • Email Alerts
    • Tear Sheet
    • Investor Presentation
    • Contacts
    • RSS News Feed

  • Stock Data

  • Quote
  • Charts
  • Historical Data

Solutions

  • Viveve System
  • InControl Products
  • Common Conditions

About

  • Mission
  • Leadership
  • Contact Us
  • Investor Information

News

  • Viveve Blog
  • Events
  • News & Publications
  • Testimonials

Resources

  • Hub Login
  • Careers with Viveve
  • Support Center
Dev Site
345 Inverness Drive South • Building B, Suite 250 • Englewood, CO 80112
The Viveve® System is an internationally patented cryogen-cooled, monopolar radiofrequency (CMRF) energy-based device. It has received regulatory approvals and clearances in many countries throughout the world and is available through physician import license in Japan. Country-specific approved indications include: • In Argentina the Viveve System is indicated for the treatment of urinary incontinence, vaginal laxity, and sexual function. • In Australia, Brazil, Canada, Chile, Colombia, Costa Rica, Dominican Republic, Hong Kong, Japan, Mexico, Panama, Philippines, Singapore, Uruguay, and Venezuela the Viveve System is indicated for the treatment of the vaginal introitus, after vaginal childbirth, to improve sexual function. • In the EU, Bahrain, Iceland, Korea, Kuwait, Lebanon, Liechtenstein, Norway, South Africa, Switzerland, and Ukraine the Viveve System is indicated for the treatment of vaginal laxity. • In Peru, Taiwan, and the United States the Viveve System is cleared for general surgical procedures for electrocoagulation and hemostasis.

Market Data copyright © 2019 QuoteMedia. Data delayed 15 minutes unless otherwise indicated (view delay times for all exchanges). RT=Real-Time, EOD=End of Day, PD=Previous Day. Market Data powered by QuoteMedia. Terms of Use.